Richard M. Wright - 13 Nov 2025 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
Former Officer
Signature
/s/ Sam Martin, attorney-in-fact for Richard M. Wright
Issuer symbol
CLDX
Transactions as of
13 Nov 2025
Net transactions value
-$490,264
Form type
4
Filing time
17 Nov 2025, 16:17:07 UTC
Previous filing
17 Jun 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wright Richard M. Former Officer C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON /s/ Sam Martin, attorney-in-fact for Richard M. Wright 17 Nov 2025 0001646423

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $61,997 +6,876 +33% $9.02 27,709 13 Nov 2025 Direct
transaction CLDX Common Stock Options Exercise $276,855 +26,672 +96% $10.38 54,381 13 Nov 2025 Direct
transaction CLDX Common Stock Options Exercise $354,060 +15,750 +29% $22.48 70,131 13 Nov 2025 Direct
transaction CLDX Common Stock Sale $1,183,177 -49,298 -70% $24.00 20,833 13 Nov 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option Options Exercise $0 -6,876 -100% $0.000000 0 13 Nov 2025 Common Stock 6,876 $9.02 Direct F2
transaction CLDX Incentive Stock Option Options Exercise $0 -26,672 -100% $0.000000 0 13 Nov 2025 Common Stock 26,672 $10.38 Direct F3
transaction CLDX Incentive Stock Option Options Exercise $0 -15,750 -67% $0.000000 7,875 13 Nov 2025 Common Stock 15,750 $22.48 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Richard M. Wright is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.05 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F2 As of June 13, 2022, the option is fully vested.
F3 As of June 18, 2024, the option is fully vested.
F4 25% vested on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.